Fibrosis (organ scarring) is a hallmark of many forms of cardiovascular and renal disease, and causes organ dysfunction and structural changes when normal tissue is replaced with scar tissue; the accumulation of scar tissue being a leading cause of death around the world. Despite deep organ scarring potentially existing in many forms (including myocardial and vascular sclerosis, renal interstitial fibrosis, and glomerulosclerosis), current therapies have only had limited success in delaying end-stage disease. The peptide hormone relaxin is emerging as a potent antifibrotic therapy with rapid-occurring efficacy. Recent studies have demonstrated the antifibrotic actions of relaxin in experimental models of cardiac and renal disease in vivo, and the various levels at which relaxin acts to inhibit fibroblast-induced collagen overproduction leading to fibrosis, in vitro. Separate studies using relaxin geneknockout mice have demonstrated the significance of endogenous relaxin as a naturally occurring and protective moderator of collagen turnover, while the therapeutic potential of relaxin has been enhanced by its ability to promote vasodilation and renal hyperfiltration. This review will summarize these coherent findings as a means of highlighting the clinical potential of relaxin in cardiovascular and renal disease. A growing body of evidence suggests that relaxin is both an endogenous regulator of fibrosis and a potential antifibrotic therapy for both developing and established fibrosis.
Relaxin is a small peptide hormone, structurally related to the insulin family of peptides and is primarily produced by the ovary and/or placenta in pregnancy and the prostate of mammals.
1,2 Humans (and higher primates) have three relaxin genes, designated H1, H2, and H3 relaxin while rodents have two genes, relaxin (equivalent to H2 relaxin) and relaxin-3 (equivalent to H3 relaxin). H2 relaxin or relaxin (in rodents) are the major source of circulating relaxin, while the primary relaxin receptor was recently identified as a G protein-coupled receptor, called the leucinerich repeat containing G protein-coupled receptor-7. Leucine-rich repeat containing G protein-coupled receptor-7 is part of a subgroup (type C) of leucine-rich repeat containing G protein-coupled receptors, that include receptors for follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone. 2, 3 Normally associated with reproduction, relaxin has been implicated in a number of pregnancy-related functions including softening the cervix and vagina at delivery. 1, 2 These actions are due in a large part to relaxin's ability to reduce collagen synthesis and increase collagen degradation via stimulation of collagenase activity. It is now becoming increasingly recognized that relaxin has a number of functions outside reproduction, with numerous reports suggesting therapeutic applications in non-reproductive processes such as fibrosis, wound healing, cardiac protection, and allergic responses. 1, 2, 4 Not only are these actions surprisingly diverse, but unlike its actions in reproductive biology, occur in both males and females.
For the purposes of this review, we will concentrate on the effect of relaxin on cardiovascular and renal disease (Table 1) .
ANTIFIBROTIC EFFECTS OF RELAXIN Functional significance of fibrosis
The disproportionate accumulation of extracellular matrix (ECM), known as scarring or fibrosis is disfiguring and, in the case of internal organs, life threatening. Renal scarring is the final common pathway to all progressive renal disease, manifesting itself in various forms affecting both the renal parenchyma (tubulointerstitial fibrosis) and vascular structures (glomerulosclerosis and vascular sclerosis). The etiology of cardiac fibrosis is similarly diverse, a consequence of not only acute inflammation (postmyocardial infarct) but also aging, increased hemodynamic load, neurohumoral activation, and metabolic disorders. Cardiac fibrosis is in particular the hallmark of hypertensive and ischemic heart diseases. Accumulation of ECM, mainly fibrillar collagens, increases tissue stiffness and impedes both contraction and relaxation of the heart, leading to organ dysfunction.
In both cardiac and renal disease, damage depends not only on the quantity of matrix produced (fibrogenesis), but also the degree of its crosslinking and its reorganization, or density. Fibrogenesis itself is dependent to a large extent on the recruitment of myofibroblasts, cells with the phenotypic features of both fibroblasts and vascular smooth muscle. Recognized by their de novo expression of a smooth muscle actin, myofibroblasts are prodigious producers of the ECM and are influenced by several mediators, including cytokines, chemokines and growth factors. 5 Furthermore, the newly synthesized matrix is remodelled by various proteases, of which the matrix metalloproteinase (MMP) family is one of the most important, 5 with the balance between fibrotic and antifibrotic signals determining the extent of scarring.
Endogenous relaxin
While the kidney and heart have certain capacity to regenerate from acute injury, so-called healing, chronic renal, and myocardial disease results in irreversible scarring. The biology of healing and scarring are similar, with the transition between the two poorly understood. Increasingly, we recognize that there are a number of naturally occurring antifibrotic factors that are required to maintain homeostasis. Relaxin may be one such molecule. In the same way that hepatocyte growth factor and bone morphogenic protein-7 downregulate transforming growth factor-beta1 (TGF-b1) signalling by interfering with Smad signal transduction, relaxin also moderates fibrogenesis at several levels, by inhibiting the influence of several profibrotic factors, inhibiting fibroblast proliferation and/or differentiation, and stimulating MMP-induced matrix degradation (reviewed in Sherwood, 1 Bathgate et al., 2 and Samuel et al.
4
).
Definitive evidence for the importance of endogenous relaxin in regulating this process has been provided by studies of the natural development of relaxin-deficient (RLXÀ/À) mice. Male RLXÀ/À mice developed an age-related progressive fibrosis in several tissues, including the kidney 6 and heart.
7 By 12 months of age, the kidney collagen concentration of male RLXÀ/À mice was 25-30% greater than levels measured in wild-type (RLX þ / þ ) animals, 6 resulting in increased cortical thickening, focal increases in interstitial fibrosis, a general diffuse increase in glomerular matrix, and renal dysfunction. An age-dependent increase in left ventricular collagen content and concentration was also more pronounced in RLXÀ/À mice than RLX þ / þ littermates. 7 These findings were associated with increased atrial hypertophy, left ventricular procollagen I mRNA expression, chamber stiffness, and diastolic dysfunction in RLXÀ/À mice from 9 months of age and onwards. These differences were however gender specific, with no such phenotype in female RLXÀ/À mice. Although the reason for this is unclear, current interest is focused on the potential compensatory role of other gender-specific hormones.
Local relaxin expression
Relaxin and/or relaxin-3 gene transcripts have been identified by RT-PCR in the rodent atria and ventricles of the heart [7] [8] [9] and the medulla and cortex of the kidney, 6 with immunohistochemistry confirming local renal expression ( Figure 1 ). Furthermore, high-affinity binding sites for relaxin have been identified in the cardiac atrium of male and female rats. 10 These combined findings suggest that the heart and kidneys are both potential sources and/or target organs for relaxin. Despite the similarity between relaxin's actions in the heart and kidney though, potentially important differences exist. Both H1 and H2 relaxin are constitutively expressed in cardiovascular tissues and upregulated in the right atria and left ventricles of patients with congestive heart failure, with the plasma levels of relaxin increasing with severity of disease. 11 Similarly, increased relaxin-3 expression was detected in the rat heart, following myocardial infarction. 9 Conversely, relaxin mRNA expression is downregulated in the kidney after unilateral ureteric obstruction (unpublished observations). However, controversy surrounds the role and significance of local relaxin synthesis.
Exogenous relaxin
A parallel, but in many ways quite distinct area of research, is the effect of exogenous relaxin. Such work has concentrated on exploring relaxin as a potential antifibrotic therapy. Relaxin has repeatedly been shown to inhibit excessive collagen accumulation in various cell culture and animal models of fibrosis (reviewed in Sherwood, 1 Bathgate et al.,
2
and Samuel et al. 4 ), ostensively a function of both its ability to decrease collagen synthesis and increase its degradation.
The production of recombinant relaxin has been a major advance in relaxin biology, providing the opportunity to undertake a number of interventionist studies. Human recombinant relaxin (H2 relaxin) is biologically active in rodents, and has formed the basis of most in vitro and in vivo studies. A number of recent in vivo studies have now clearly shown that exogenous relaxin is able to moderate the progression of disease in several experimental rodent models of renal fibrosis.
6,12-15 Continuous 2-to 4-week-infusion of relaxin with osmotic minipumps was shown to ameliorate fibrosis in several animal models. Morphometric studies in a rat model of bromoethylamine-induced renal papillary necrosis demonstrated that 28 days of H2 relaxin infusion decreased the fractional area of interstitial collagen staining by 75%. This was associated with a parallel reduction in immunoreactive TGFb1, macrophage infiltration and a preservation of glomerular filtration rate. 12 Similar effects were seen in both ablative and infarction models of 5/6 nephrectomy. There was a decrease in hypertension in the infarction model, but no change in blood pressure in the normotensive ablation model, suggesting that the preservation of glomerular filtration rate may be both blood pressure dependent and independent. 13 Likewise, relaxin decreased focal glomerulosclerosis and interstitial fibrosis in an antiglomerular basement membrane nephritis model of disease.
14 While a means of preventing fibrogenesis is important, the ability to remove established fibrosis represents the 'holy grail. ' The clinical reality is that many renal patients present with chronic disease, and therefore, established fibrosis. Again, studies of the natural history of RLXÀ/À mice have provided valuable insights. Treatment of established renal 6 and cardiac 8 fibrosis in 12-month-old RLXÀ/À mice for only 2 weeks with recombinant H2 RLX successfully reduced collagen deposition, albeit to levels still greater than that seen in RLX þ / þ mice ( Figure 2 ). Infusion of recombinant H2 relaxin for a period of 14 days also reversed cardiac fibrosis by 58% in transgenic animals overexpressing b2 adrenergic receptors, 8 which ultimately undergo heart failure. Studies of relaxin in the spontaneously hypertensive rat 15 integrate cardiovascular and renal work well, with these studies showing that short-term perfusion of exogenous relaxin also ameliorated established fibrosis. Administration of H2 relaxin to 9-to 10-month-old spontaneously hypertensive rats led to a significant decrease in the collagen content within the left ventricular myocardium and kidney, but did not effect collagen in the unaffected chambers of the heart (including the right ventricle and atria). These combined studies therefore suggest that relaxin is an endogenous protective factor in the heart and kidney, having the potential to limit fibrogenesis, while exogenous relaxin has potent antifibrotic properties.
Mechanism of relaxin's antifibrotic properties in vitro studies
The ability of relaxin to downregulate collagen production and increase collagen-degradation is central to its physiological role. How it achieves this is however less clear. In vitro studies probably provide the best insights into this process. H2 relaxin acts directly on TGF-b1-stimulated renal fibroblasts to decrease myofibroblast differentiation 16 and collagen secretion by rat 16 and human 17 cells while increasing expression of the interstitial collagen degrading enzyme, MMP-13, the rat homologue of MMP-1. 16 Using gelatin zymography, Heeg et al. 17 also reported a relaxin-induced significant increase in MMP-2 secretion, with a smaller more variable effect on MMP-9. However, the in vivo benefits of increased MMP-2 activity may be ambiguous, as MMP-2 degradation of tubular basement membranes is an important part of epithelial-mesenchymal transition, a major source of fibroblasts in renal disease. 18 The effect of relaxin on renal scarring is not confined to the collagen constituents of the ECM, with H2 relaxin inhibiting fibronectin expression in fibroblasts, 14, 17 tubular, 14 and mesangial cell cultures, 14 presumed to be through an increase in ubiquitin-dependent degradation rather than a reduction in fibronectin mRNA.
14 Conversely, studies of renal fibroblast kinetics have reported that relaxin has little 17 if any 16 effect on fetal calf serumstimulated mitogenesis.
Cardiac fibroblasts and myofibroblasts are likewise the cellular basis of ECM synthesis and remodelling in the heart. Relaxin abrogated TGF-b1 and angiotensin II-stimulated fibroblast proliferation, a smooth muscle actin expression, collagen synthesis and deposition in neonatal (atrial and ventricular) cardiac fibroblasts, which along with cardiomyocytes, naturally express the leucine-rich repeat containing G protein-coupled receptor-7 receptor. 8 Additionally, both latent and active forms of MMP-2 were increased (60 and 25%, respectively), once again with no marked effect on MMP-9 expression. 8 A consistent in vitro finding is therefore that relaxin often only affects TGFb1 stimulated and not basal fibrogenesis in these cells.
Recent studies in renal fibroblasts suggested that the effects of relaxin were mediated to a large extent by the Smad pathway. 17 Phosphorylation of Smad2 and 3, formation of complexes with Smad4, and translocation of these complexes from the cytosol to the nucleus are key events in TGFb1 signalling. Relaxin inhibited the phosphorylation and translocation of Smad2 to the nucleus, in the absence of any effects on phosphorylation of Smad3, c-Jun NH 2 -terminal kinase 1/2, extracellular signal-regulated protein kinase, or p3MAP kinase. 17 These findings therefore raise the possibility that relaxin may lower collagen overexpression in affected organs without affecting basal expression in unaffected tissues, making it a highly desirable therapeutic agent for prevention of aberrant fibrosis. It is important to note that while several actions of relaxin are consistently identified in multiple organs, some of its actions are tissue specific or vary between organs, suggesting that relaxin inhibits fibrosis through common and specific mechanisms, depending on the organ it is applied to.
HEMODYNAMIC EFFECTS OF RELAXIN
In addition to its well-documented antifibrotic actions in the kidney and heart, relaxin plays a number of other roles in these organs, highlighting its diverse, but related protective effects.
While the kidney and other vascular organs are known to dilate during pregnancy, the factor(s) responsible for this dilation were poorly understood, until Conrad and co-workers elucidated that relaxin was the hormone involved in renal vasodilation and hyperfiltration. 19 H2 relaxin was shown to increase effective renal plasma flow and glomerular filtration rate, attenuate the renal circulatory response to angiotensin II and reduce plasma osmolality regardless of gender. 19 Relaxin was also shown to reduce the myogenic reactivity of small renal arteries of both pregnant 20 and conscious non-pregnant 21 rats in vivo, while dilating small and large arteries of several reproductive and non-reproductive organs in vitro, leading to decreased blood pressure and increased coronary, 22 renal, and uterine blood flow. These relaxin-induced effects were biphasic, whereby low doses were associated with vasodilation and a reduction in plasma osmolality, while high doses were relatively inactive. 19, 21 Furthermore, both human and porcine relaxin were able to potently antagonize renal and cardiac vasoconstriction in response to endothelin (ET)-1 and angiotensin II, 11, 19 an effect seen in mesenteric vessels of spontaneously hypertensive rats, bovine aorta smooth muscle cells and rat coronary endothelial cells.
From these combined findings, it has been hypothesized that relaxin may induce its hemodynamic effects in the cardiovascular and renal systems via a number of possible mechanisms. Firstly, relaxin has repeatedly been shown to stimulate coronary flow, 22 renal vasodilation and hyperfiltration 19 by increasing nitric oxide (NO) production, via stimulation of nitric oxide synthase (NOS). This action was blocked by nitric oxide synthase inhibitors, suggesting a NOdependent mechanism. Secondly, relaxin's actions on ET were thought to be mediated through the ETB receptor subtype, as it was this receptor subtype that was specifically involved in ET-induced stimulation of intracellular calcium in endothelial cells, prostacyclin and NO. 19 An essential role for the endothelial ETB receptor subtype in the renal vasodilation, hyperfiltration and reduced myogenic reactivity of small renal arteries was initially established in relaxin-treated rats. 19 However, controversy surrounds whether relaxin directly stimulates the ETB receptor. While Conrad and co-workers did not detect a relaxin-induced upregulation of ETB receptor protein expression, 23 they were able to demonstrate that a relaxin-induced increase in vascular gelatinase (MMP-2) activation led to the processing of ET-1 to ET1-32, 24 thereby stimulating the ETB receptor and NO production in rat renal vessels/vasculature. Furthermore, renal vasodilation and hyperfiltration were completely blocked in relaxintreated rats by a specific peptide inhibitor of the gelatinases. 24 In separate studies though, Dschietzig et al. 25 were able to report a relaxin-induced upregulation of ETB receptor expression in human and bovine cell types in vitro and in rat thoracic aortas, renal and mesenteric arteries ex vivo. Thus, from both studies 24, 25 it was concluded that relaxin was able to mediate its vasodilatory effects via regulation of the ETB receptor (either directly or indirectly) and increased NO production.
OTHER EFFECTS OF RELAXIN
In addition to its actions detailed above, relaxin has also been shown to have other important roles in the heart and kidney, confirming that these organs are targets for relaxin binding and activity. Relaxin induces potent, direct and concentrationdependent chronotropic and ionotropic effects in the rat heart (reviewed in Sherwood, 1 Bathgate et al., 2 and Samuel et al.
4
). The relaxin-induced increase in heart rate has been demonstrated in vivo, in spontaneously hypertensive rats 15 and ex vivo in the isolated perfused intact heart, left and right atria, and ventricular tissue. However, relaxin failed to induce a chronotropic effect in the human heart, 4 questioning the significance of this effect in non-rodent species. In separate studies, relaxin has been reported to stimulate angiogenesis and wound healing, by stimulating new blood vessel formation, enhanced granulation tissue formation and increased vascular endothelial growth factor and basic fibroblast growth factor expression at wound sites in a rat myocardial infarct model. 26 These findings demonstrated that relaxin was able to increase the vascular supply to injured tissues, resulting in increased wound healing (reviewed in Sherwood, 1 Bathgate et al., 2 and Samuel et al. 4 ). Relaxin has also been shown to counteract myocardial damage induced by ischemia reperfusion, by increasing coronary flow and NO production, while decreasing calcium overload and infiltration of inflammatory cells. 27 
SUMMARY AND CONCLUSIONS
Relaxin is able to induce its effects via common and organspecific mechanisms, primarily involving the inhibition of the influence of profibrotic factors, fibroblast differentiation and collagen production in addition to an increase in MMPinduced collagen degradation. However, despite its promise, there are a number of key questions to be answered. Most of our understanding of relaxin biology comes from studies in rodents. Given the extent to which relaxin biology varies among species, it is unclear how much of this applies to humans. Furthermore, the significance of relaxin expression at secondary sources, and that of its receptor, is controversial, but is becoming increasingly studied, while the requirement for continuous infusion of the hormone continues to remain a major clinical obstacle.
Not withstanding the above problems, the use of a naturally occurring inhibitor of fibrosis, with a welldocumented ability to remove established collagen, albeit in animals models, offers great potential. Studies of relaxin and its receptor offer an exciting opportunity for us to better understand the biology of both cardiovascular and renal disease in general.
